Drug Trial Radar · NCT04175171
Clinical Trial of Comparative Study of GB221 Pharmacokinetics
Last checked: Nov 19, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Nov 7, 2011
Primary completion
Jan 8, 2012
Study completion Mar 8, 2012
Sponsor
- Lead sponsor
- Genor Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to assess the safety of a single dose of GB221 compared to Herceptin® when administered as a single IV injection at a dose of 8 mg/kg. The secondary objective of the study is to assess the pharmacokinetics of GB221 compared to Herceptin®.
Conditions
- Metastatic Breast Cancer
Interventions
Coprelotamab InjectionDrug
The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.
Trastuzumab InjectionDrug
The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
Primary outcomes
What the sponsor says the trial is designed to measure.
- physical examinationTime frame: Up to 84 days
- adverse eventTime frame: Up to 84 days
- blood pressureTime frame: Up to 84 days
- heart rateTime frame: Up to 84 days
- respiration rateTime frame: Up to 84 days
- oxygen saturationTime frame: Up to 84 days
- temperatureTime frame: Up to 84 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Linear Clinical Research Limited
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.